Advanced or Metastatic Soft Tissue Sarcomas (STS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Soft tissue sarcomas (STS), aggressive mesenchymal-origin tumors, represent 1% of all adult malignancies, with the World Health Organization recognizing over 50 distinct histological subtypes. Currently, the primary treatment strategy for localized STS involves surgery, optionally supplemented with perioperative chemotherapy. For patients with advanced or metastatic STS, the first-line treatment typically consists of palliative anthracycline-based chemotherapy administered either alone or in combination with ifosfamide. This applies to most STS subtypes. STS is known for their aggressive nature and propensity to infiltrate deep tissues. They exhibit a high recurrence rate of 35%, and in 16% of all cases, metastasis is already present at the time of diagnosis, predominantly affecting the lungs. The Overall Survival (OS) for patients with advanced metastatic STS is approximately 12 months. However, recent studies involving newer drugs have extended OS to 18 months. Interestingly, a subset of patients with metastatic STS can remain asymptomatic for extended periods, even in the absence of active treatment.

Thelansis’s “Advanced or Metastatic Soft Tissue Sarcomas (STS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic Soft Tissue Sarcomas (STS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Advanced or Metastatic Soft Tissue Sarcomas (STS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Advanced or Metastatic Soft Tissue Sarcomas (STS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Advanced or Metastatic Soft Tissue Sarcomas (STS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033